- Conditions
- Peripheral Arterial Disease (PAD)
- Interventions
- ferumoxytol
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Aortoiliac Occlusive Disease, Peripheral Arterial Disease
- Interventions
- Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 20 more
- Conditions
- Aortoiliac Occlusive Disease
- Interventions
- GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Fresno, California • Tampa, Florida • Rochester, Minnesota + 16 more
- Conditions
- Aortic Aneurysm, Abdominal, Abdominal Aortic Occlusion, Aortoiliac Occlusive Disease, Aortic Diseases
- Interventions
- Liposomal bupivacaine, Ropivacaine, Bupivacain
- Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut